Clinical trials: Adenovirus Infection
Non-Small Cell Lung Cancer
Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung Cancer
The purpose of this trial is to examine the safety and immunogenicity of a therapeutic vaccine regimen with recombinant DNA and adenovirus expressing L523S protein in patients with early stage non-small cell lung cancer.
- Trial name
- NCT00062907
- Testing
- Recombinant DNA- pVAX/L523S, Recombinant adenovirus- Ad/L523S
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- Corixa Corporation
Viral Conjunctivitis
Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Epidemic Keratoconjunctivitis (EKC)
A randomized, double-masked, placebo-controlled, multi-centre phase IIa proof-of-concept study to evaluate efficacy and safety of APD-209 Eye drops for treatment of acute phase adenovirus-induced EKC.
- Trial name
- NCT01977443
- Testing
- APD-209 Eye drops
- Where
- 10 sites in Germany, Poland and 1 more
- Volunteers
- 47 people
- Sponsor
- Adenovir Pharma AB
Norovirus Infections
A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult Volunteers
Subjects will receive multiple sub-doses over a 4-hour period to deliver a total overall dose of 1E11. Evaluations of immunogenicity, safety, and tolerability will be evaluated.
- Trial name
- (VXA-G1-1-NN) (NCT05213728)
- Testing
- VXA-G1.1-NN
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Vaxart
Virus Diseases
A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children
The purpose of this study is to assess the safety and reactogenicity of a single IM dose of the GSK3390107A (ChAd3 EBO-Z) vaccine, overall and in children aged 1 to 5, 6 to 12, and 13 to 17 years, separately.
- Trial name
- NCT02548078
- Testing
- GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A), Nimenrix powder and solvent for solution for injection in pre-filled syringe; Meningococcal group A, C, W-135 and Y conjugate vaccine
- Where
- 2 sites in Mali, Senegal
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Adenovirus
Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
Provide patients with serious AdV infection or disease access to treatment with BCV.
- Trial name
- NCT02596997
- Testing
- Brincidofovir
- Where
- 46 sites in United States
- Sponsor
- Jazz Pharmaceuticals
Healthy
A Study to Evaluate the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants
The purpose of this study is to test the safety and immunogenicity of MVA-BN-Filo and Ad26.ZEBOV administered as heterologous prime-boost vaccine regimens in healthy adult participants.
- Trial name
- NCT02376426
- Testing
- MVA-BN-Filo, Ad26.ZEBOV
- Where
- Kenya
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Hepatocellular Carcinoma
SynOV1.1 Intratumoral Injection Study
This is a Phase I, open-label, multicenter study to characterize safety and tolerability, evaluate biodistribution, biological effects and immunogenicity, and evaluate the preliminary clinical efficacy of SynOV1.1 in participants…
- Trial name
- NCT04612504
- Testing
- SynOV1.1
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Beijing Syngentech Co., Ltd.
Adenovirus Disease
Phase 2 Study to Evaluate Brincidofovir for the Prevention of Adenovirus Disease
This study was designed to assess the safety and efficacy of preemptive treatment with oral brincidofovir (BCV), as compared to placebo, for the prevention of adenovirus (AdV) disease in recipients of hematopoietic stem cell…
- Trial name
- NCT01241344
- Testing
- Brincidofovir
- Where
- 30 sites in United States
- Volunteers
- 52 people
- Sponsor
- Jazz Pharmaceuticals
Lymphoma, B-Cell
Study to Evaluate the Safety and Efficacy of Adeno-IFN Gamma in Cutaneous B-cell Lymphoma
The primary objective of this study is to evaluate the efficacy of a four-month dosing period of intra-lesional injection of TG1042 in patients with relapsing CBCL.
- Trial name
- NCT00394693
- Testing
- Adenovirus Interferon gamma
- Where
- 6 sites in United States, France and 1 more
- Volunteers
- 13 people
- Sponsor
- Transgene
Melanoma
Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma
This research study involves two investigational drugs, an Activator Ligand (INXN-1001) in combination with an Adenovirus Vector Engineered to Express hIL-12 (INXN-2001).
- Trial name
- NCT01397708
- Testing
- INXN-2001, INXN-1001
- Where
- 9 sites in United States
- Volunteers
- 26 people
- Sponsor
- Alaunos Therapeutics
Healthy
A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health
The purpose of this study is to demonstrate the non-inferiority of the concomitant administration of an adenovirus serotype 26- based vaccine encoding for the respiratory syncytial virus pre-fusion F protein (Ad26.RSV.preF) and…
- Trial name
- NCT03339713
- Testing
- Ad26.RSV.preF, Fluarix
- Where
- United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Solid Tumor
TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy
This is an open-label, phase 1, dose-escalation, multicenter trial evaluating the safety of oncolytic adenovirus TILT-123 as monotherapy in advanced solid tumor patients.
- Trial name
- TUNIMO (NCT04695327)
- Testing
- TILT-123
- Where
- 2 sites in Finland
- Volunteers
- 32 people
- Sponsor
- TILT Biotherapeutics Ltd.
Viral Conjunctivitis
ADenoVirus Initiative Study in Epidemiology in Italy
The objectives of this study is to assess the characteristics and frequency of adenovirus conjunctivitis in a population of male and female patients from one year of age who present signs and symptoms of acute conjunctivitis.
- Trial name
- NCT03055065
- Where
- Italy
- Volunteers
- 241 people
- Sponsor
- NicOx
Malaria
A Study to Assess the Immunogenicity, Tolerability and Safety of a Malaria Vaccine and Also Its Protective Efficacy in a Malaria Challenge Model
The purpose of this study is to assess the safety, tolerability and immunogenicity of two dose levels (1x10^10 and 5x10^10 virus particles (vp)) of the adenovirus serotype (Ad) Ad35.CS.01/Ad26.CS.01 prime-boost malaria candidate…
- Trial name
- NCT01397227
- Testing
- Ad35.CS.01/Ad26.CS.01 low dose (1 x 10^10 vp), Ad 35.CS.01/Ad 26.CS.01 high dose (5 x 10^10 vp)
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Coronary Artery Disease, Ischemia
Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment (The EXACT Trial)
The primary purpose of this trial is to determine the safety of XC001 (AdVEGFXC1) in patients who suffer from angina caused by coronary artery disease and have no other treatment options.
- Conditions
- Coronary Artery Disease, Ischemia, Angina Refractory, Cardiovascular Diseases
- Trial name
- EXACT (NCT04125732)
- Testing
- AdVEGFXC1
- Where
- 16 sites in United States
- Volunteers
- 41 people
- Sponsor
- XyloCor Therapeutics, Inc.
Respiratory Syncytial Virus Prevention
A Study of Adenovirus Serotype 26.Respiratory Syncytial Virus.Pre-Fusion F (Ad26.RSV.preF)-Based Vaccine for Prevention of Respiratory Syncytial Virus (RSV) Mediated- Lower Respiratory Tract Disease (LRTD) in Japanese Participants
The purpose of the study is to evaluate the efficacy of study vaccine in the prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-confirmed RSV mediated- lower Respiratory Tract Disease (LRTD) over one RSV…
- Trial name
- NCT05242432
- Testing
- Ad26/protein preF RSV Vaccine
- Where
- 30 sites in Japan
- Volunteers
- 2,192 people
- Sponsor
- Janssen Pharmaceutical K.K.
Mucopolysaccharidosis Type III A, Sanfilippo Disease Type A
Intracerebral Gene Therapy for Sanfilippo Type A Syndrome
The clinical trial P1-SAF-301 is an open-label, single arm, monocentric, phase I/II clinical study evaluating the tolerance and the safety of intracerebral administration of adeno-associated viral vector serotype 10 carrying the…
- Trial name
- NCT01474343
- Testing
- SAF-301
- Where
- 2 sites in France
- Volunteers
- 4 people
- Sponsor
- LYSOGENE
Brain Cancer, Central Nervous System Diseases
DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas
The goal of this clinical research study is to find the highest tolerable dose of DNX-2401 that can be injected directly into brain tumors and into the surrounding brain tissue where tumor cells can multiply.
- Trial name
- NCT00805376
- Testing
- DNX-2401, Tumor Removal
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- DNAtrix, Inc.
Hepatitis B Virus (HBV)
Safety and Efficacy of Therapeutic Hepatitis B Adenovirus Injection (T101) Combined With Nucleoside (Acid) Analogues in Chronic Hepatitis B Patients
A multi-center, randomized, open-label, group controlled study to evaluate the safety and efficacy of T101 combined with nucleoside (acid) analogues in chronic hepatitis B patients.
- Trial name
- NCT04189276
- Testing
- ETV/TDF+T101 No.1, ETV/TDF+T101 No.2, ETV or TDF
- Where
- 3 sites in China
- Volunteers
- 100 people
- Sponsor
- Tasly Tianjin Biopharmaceutical Co., Ltd.
Solid Tumor
A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Malignant Solid Tumors
This is a Phase 1 open-label study to evaluate the safety, tolerability, and pharmacokinetics of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) at dose of 5×10∧9VP、5×10∧10VP、5×10∧11VP in Patients With…
- Trial name
- NCT06215846
- Testing
- BioTTT001 injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Beijing Bio-Targeting Therapeutics Technology Co., Ltd